替考拉宁治疗医院获得性肺炎影响预后的因素分析

Influencing factors for prognosis of hospital-acquired pneumonia patients treated with teicoplanin

目的探讨替考拉宁治疗耐甲氧西林金黄色葡萄球菌医院获得性(MRSA)肺炎预后的影响因素,为临床治疗提供依据。方法回顾性分析医院呼吸重症科替考拉宁治疗医院获得性肺炎患者35例,收集临床资料,分析影响预后的因素,采用SPSS17.0软件对数据进行统计处理。结果 35例患者中经验治疗18例占51.43%,目标治疗17例占48.57%,替考拉宁治疗天数经验治疗组明显长于目标治疗组,14d死亡例数经验治疗组明显低于目标治疗组,经验治疗组治疗成功例数明显多于目标治疗组,差异有统计学意义(P<0.05);35例医院获得性MRSA患者中治疗失败15例占42.85%,其中13例死亡,病死率37.14%。结论影响替考拉宁治疗医院获得性肺炎预后的因素有年龄、治疗时间及经验性应用替考拉宁,经验性应用替考拉宁可降低病死率。

OBJECTIVE To explore the influencing factors for prognosis of the patients with methicillin-resistant Staphylococcus aureus （MRSA） hospital-acquired pneumonia who were treated with teicoplanin so as to guide the clinical treatment .METHODS The retrospective study was conducted for 35 patients with hospital-acquired pneumonia who were treated with teicoplanin in the severe respiratory department ,the clinical data were collected , the influencing factors for the prognosis were analyzed ,and the statistical analysis was performed with the use of SPSS17 .0 software .RESULTS Of the 35 patients , 18 cases received the empirical therapy , accounting for 51 .43% ;17 cases received the targeted therapy , accounting for 48 .57% . The duration of treatment with teicoplanin was significantly longer in the empirical therapy group than in the targeted therapy group ;the 14-day mortality rate of the empirical therapy group was significantly lower than that of the targeted therapy group ;the success rate of treatment was significantly higher in the empirical therapy group than in the targeted therapy group （P〈0 .05） .Of the 35 patients with hospital-acquired MRSA ,the treatment failed in 15 （42 .85% ） cases ,and 13 cases died with the mortality rate of 37 .14% .CONCLUSIONS The influencing factors for the prognosis of the hospital-acquired pneumonia patients treated with teicoplanin include the age ,duration of treatment ,and empirical use of teicoplanin ;the empirical use of teicoplanin can reduce the mortality rate .